Introduction
Contact tracing to combat the spread of sexually transmitted diseases (STDs) was instituted in 1937 by the US Surgeon General.' In 1943 it was developed in the UK when the Medical Officer of Health for Newcastle upon Tyne, Dr John Charles, inaugurated the "Tyneside Scheme" to include the County Councils of Durham and Northumberland and the County Borough Councils of Gateshead, Newcastle upon Tyne, Tynemouth and South Shields.' The "Scheme" was a local authority initiative which included an education programme for all interested in fighting venereal disease, the routine serological testing of antenatal cases for syphilis as well as the inauguration of contact tracing. There is therefore a long tradition of contact tracing in Newcastle.
The terminology has altered over the years and now in the USA "contact tracing" equates with "provider referral" in which named partners of infected individuals are located and counselled by health care staff. 3 The term "partner notification" has been advocated by the World Health Organisation and the Centers for Disease Control4 5 to include both "provider referral" and "patient referral" in which patients or "index cases" notify their partners themselves, often coached and advised by health care staff. This covers the spectrum of activities in which sexual and needle-sharing partners of persons with HIV infection are notified and counselled about their exposure. Throughout this paper we shall use the terms partner notification, provider referral and patient referral as defined above.
The value of partner notification for the control of sexually transmitted infections is well recognized.6 It can reduce the number of cases of gonorrhoea and syphilis as compared with the numbers anticipated and has helped to control outbreaks of these diseases. 7 8 Even in genital chlamydial infection with a longer and more uncertain incubation period the benefit of detecting asymptomatic carriage of Chlamydia trachomatis has been clearly demonstrated. 9 As part of the management of human immunodeficiency virus (HIV) 
Discussion
Partner notification followed by counselling and testing has identified 25 new seropositive cases from the 79 people attending on this basis (excluding the man who declined testing). This figure of 31.6% compares favourably with studies from other countries with emphasis on provider referral. In Sweden"1 15% of contacts with previously unknown infection were found to be seropositive. A Norwegian study has shown a 13% seropositivity rate17. Reports from the USA indicate that the seroprevalence rate arising from partner notification varies from 7-42%'0 14 where most states require seropositive people to be reported to the Department of Health.
Our figures for the percentage of partners who have been informed of their risk and of the numbers who subsequently attended for counselling and testing include only those people for whom we have hard evidence. More may have attended without disclosing their identities or that their partners had asked them to attend. There may be others who plan to attend but have yet to find the time and courage to do so. Should they develop symptoms in the meantime they will have knowledge which may lead to an accurate, early diagnosis of their illness.
Our figure of 31.6% demonstrates the success of operating a voluntary, confidential notification system. New index cases are given as much time, advice and support to initiate patient referral or supply information for provider referral as is required. The basic principles are (a) not to disclose the source of infection and (b) not to disclose the name of the infection unless exceptionally a relevant screening test offered is declined by the contact. These principles are brought to the attention of the index case before further action is taken. This system has operated successfully in the UK for years for other STDs and has been extended to include HIV infection.
Keenleyside et al 18 We have not been aware of any misgivings from our patients regarding partner notification as has also been shown in the USA'9.
Although the number of people tested fell from a peak of 1698 in 1987 to 576 in 1989 there has been a steady increase to 1484 in 1991 and 880 for the first half of 1992. Our policy of partner notification has been consis-tent but the demand for testing has apparently increased as the potential benefits of being aware of one's serostatus take precedence over the perceived threats of the test.
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